Optimisation of the formulation of AmacaGel for therapeutic applications

用于治疗应用的 AmacaGel 配方优化

• 批准号: CCARD-2022-00479
• 负责人: LeRoy, Julien
• 金额: $ 2.91万
• 依托单位: La Cité collégiale
• 依托单位国家: 加拿大
• 项目类别: CCI Applied Research and Development Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=746409
• 关键词: Optimisation; formulation; AmacaGel; therapeutic; applications

AmacaThera is a drug and cell delivery company based in Toronto developing a unique biomaterial technology - AmacaGel - for drug and cell delivery-based medical applications. The company would like to partner with the scientist of the Technology Access Center in Bio-Innovation from the college La Cité in Ottawa to deliver cell-based therapies to treat traumatic brain injury, blindness, and spinal cord injury and other high-unmet need indications using their technology. The aim of the project is to screen various excipients that can be combined with AmacaGel to support long-term cryo-storage of the cell-gel products.

AmacaThera是一家总部设在多伦多的药物和细胞输送公司，正在开发一种独特的生物材料技术--AmacaGel，用于基于药物和细胞输送的医疗应用。该公司希望与渥太华La Cité学院生物创新技术获取中心的科学家合作，利用他们的技术提供基于细胞的疗法，以治疗创伤性脑损伤、失明、脊髓损伤和其他高度未满足的适应症。该项目的目的是筛选能够与AmacaGel结合的各种赋形剂，以支持细胞凝胶产品的长期冷冻储存。